Drug intelligence / Profile preview

Meksibel

Development stage: Phase 1
Lead developer: Vitebsk State Medical University
Modality: Small Molecules

Overview

Meksibel is a small molecule drug under investigation for use in digestive system disorders, with specific research interest in the prevention of acute pancreatitis after endoscopic interventions. Its highest reported development status is "Pending," and it has been studied in at least one Phase 1 clinical trial for the prevention of acute pancreatitis following minimally invasive bile duct procedures. The precise mechanism of action, molecular target, and active ingredient are not specified in available public sources as of June 2025[9].

Brand names: Meksibel

Beyond the preview

Go deeper on Meksibel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meksibel.

Explore the full profile